Moderna stock (NYSE:MRNA) rose to prominence during the pandemic owing to its coronavirus vaccine. The stock price followed suit, rising 434% by 2020. However, demand for vaccination stocks has declined since then. Moderna’s stock (NYSE:MRNA) has dropped.
Simultaneously, another biotech startup, Axsome Therapeutics (AXSM), is receiving its due. So far, Axsome stock (NASDAQ:AXSM) has resisted the bad market. This is when the company’s initial items are released.
Regardless of current stock performance, both firms have bright possibilities for the future. The issue now is, which of these dynamic biotech businesses is the best investment right now?
The Moderna Stock Argument
So far this year, Moderna stock (NYSE:MRNA) has fallen by half. Yes, Moderna is now making billions of dollars from their coronavirus vaccine. However, investors are concerned about vaccination or booster sales in a post-pandemic scenario.
These fears may be exaggerated. According to Moderna, after the epidemic, the vaccine business in the United States may be worth up to $13 billion. International markets might contribute to this. These figures do not lead to vaccine sales exceeding this year’s $21 billion forecast. However, they leave Moderna with a blockbuster product and lots of funds to finance the pipeline.
Moderna has two phases 3 initiatives in terms of its pipeline that potentially lead to commercial releases coming in the following two to three years: influenza vaccine candidates and respiratory syncytial virus vaccine candidates (RSV). Both of these have the multibillion-dollar potential for Moderna.
The Axsome Argument
When it comes to growth, Axsome stock (NASDAQ:AXSM) is just getting started. It isn’t yet generating billions of dollars like Moderna. But it could make it. According to GlobalData, the business just received regulatory clearance for Auvelity, a therapy for a severe depressive illness that may generate $1.3 billion in sales by 2029.
The antidepressant market is oversaturated. However, Auvelity’s fast action (it relieves symptoms in only one week) may help it outperform its competitors. Most antidepressants take weeks to take effect.
So, if everything goes well, we might have three marketable medications within the next several years. And more might come soon after. This is because Axsome’s other four pipeline products are in phase 2 or phase 3 studies.
Axsome stock (NASDAQ:AXSM) has gained 28% so far this year, with the majority of that increase occurring in the last few months. However, given the number of expected product approvals in the next few years, there is still space for a rise in stock prices.
Axsome or Moderna?
Both firms have bright futures. Over the following few years, they hope to make money from not just one but multiple goods. They both have late-stage prospects in their pipelines as well.
But if I had to pick only one, of these stocks right now, it would be Moderna. Moderna, which has declined this year, may provide more significant comeback potential – even if that bounce may not occur overnight.
All of this suggests that Moderna has won the better-buy battle today.
Featured Image – Megapixl © PhotoGranary
Author Okoro Chinedu 
